semaglutide and cardiovascular outcomes in obesity AHA Late Breaking Science: Day 1 Highlights 🫀SELECT Trial: without Diabetes ✓: ⬇️ 20% Risk of a composite of cardiovascular death ❤️, nonfatal myocardial infarction, or Are Ozempic and Wegovy “game-changers”

How to Avoid It: Always check the expiration date before using a new vial

Nausea from retatrutide, like other GLP-1 agents, is primarily caused by the slowing of gastric emptying food moves through your stomach more slowly, which triggers nausea signals

In 2005, the first GLP-1 receptor agonist, exenatide (marketed as Byetta), was approved by the US Food and Drug Administration and subsequently received European authorisation through the European Medicines Agency (EMA)

Suddenly stopping semaglutide could lead to rebound weight gain, so it is crucial for women to communicate openly with their providers. Dr

Your red blood cells need iron and folic acid to function properly